Developed by Eli Lilly (the same company behind weight management injection Mounjaro), Retatrutide has shown promising early results in clinical trials for reducing body weight - in some cases even more significantly than current medications like Wegovy (semaglutide) or Mounjaro (tirzepatide)
(2006) Blockade of pancreatic islet-derived ghrelin enhances insulin secretion to prevent high-fat diet-induced glucose intolerance
Best practice: Match the peptide to the severity of the metabolic model (Standard obesity/T2D = Tirzepatide, Severe obesity/Lipolysis = Retatrutide)
Semaglutide, a GLP-1 Receptor Agonist Semaglutide is the active ingredient behind Ozempic and Wegovy
MASLD associated with increased alcohol consumption (2050 g/day for females and 3060 g/day for males) is defined as MetALD, 2 and individuals in this population may have previously been diagnosed with alcohol-related liver disease (ALD)
Understanding the factors that influence an individuals response, such as baseline BMI, sex, and comorbidities, will be crucial in guiding the selection of the most appropriate treatment approach
